candesartan cilexetil has been researched along with Hypertension, Essential in 3 studies
candesartan cilexetil: a prodrug which is metabolized to an active form candesartan to exert its biological effects
| Excerpt | Relevance | Reference |
|---|---|---|
| " The purpose of this study was to explore the optimal dosage of a fixed-dose combination of candesartan cilexetil (CAN) and amlodipine besylate (AML), by examining the tolerability and efficacy of CAN/AML combination therapy compared with those of monotherapy with either drug in patients with essential hypertension." | 9.24 | Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension: A Phase II Multicenter, Randomized, Double-blind Clinical Trial. ( Ahn, T; Chae, SC; Cho, EJ; Cho, JH; Choi, JY; Chung, WB; Hong, TJ; Ihm, SH; Jeon, HK; Jeong, MH; Kim, CJ; Kim, WS; Kim, YK; Lee, HY; Lee, JH; Nam, CW; Park, JI; Park, SM; Shin, ES; Sohn, IS; Yang, TH; Yoon, JH; Youn, HJ, 2017) |
| " The primary assessment included the incidence of treatment-emergent adverse events (TEAEs)." | 6.82 | Fixed-dose combination of nifedipine gastrointestinal therapeutic system and candesartan cilexetil in patients with moderate-to-severe essential hypertension: an open-label, long-term safety and efficacy study. ( Dzongowski, P; Kjeldsen, SE; Li, N; Radlmaier, A; Wang, L, 2016) |
| " The purpose of this study was to explore the optimal dosage of a fixed-dose combination of candesartan cilexetil (CAN) and amlodipine besylate (AML), by examining the tolerability and efficacy of CAN/AML combination therapy compared with those of monotherapy with either drug in patients with essential hypertension." | 5.24 | Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension: A Phase II Multicenter, Randomized, Double-blind Clinical Trial. ( Ahn, T; Chae, SC; Cho, EJ; Cho, JH; Choi, JY; Chung, WB; Hong, TJ; Ihm, SH; Jeon, HK; Jeong, MH; Kim, CJ; Kim, WS; Kim, YK; Lee, HY; Lee, JH; Nam, CW; Park, JI; Park, SM; Shin, ES; Sohn, IS; Yang, TH; Yoon, JH; Youn, HJ, 2017) |
| " The primary assessment included the incidence of treatment-emergent adverse events (TEAEs)." | 2.82 | Fixed-dose combination of nifedipine gastrointestinal therapeutic system and candesartan cilexetil in patients with moderate-to-severe essential hypertension: an open-label, long-term safety and efficacy study. ( Dzongowski, P; Kjeldsen, SE; Li, N; Radlmaier, A; Wang, L, 2016) |
| "Essential hypertension is a chronic pathology that causes long-term complications due to late diagnosis of patients, the inability to control the disease through medication, or due to the complexity of associated risk factors." | 1.43 | Evaluation of patients diagnosed with essential arterial hypertension through network analysis. ( Buda, V; Cristescu, C; Suciu, L; Tomescu, MC; Topîrceanu, A; Udrescu, L; Udrescu, M, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sohn, IS | 1 |
| Kim, CJ | 1 |
| Ahn, T | 1 |
| Youn, HJ | 1 |
| Jeon, HK | 1 |
| Ihm, SH | 1 |
| Cho, EJ | 1 |
| Chung, WB | 1 |
| Chae, SC | 1 |
| Kim, WS | 1 |
| Nam, CW | 1 |
| Park, SM | 1 |
| Choi, JY | 1 |
| Kim, YK | 1 |
| Hong, TJ | 1 |
| Lee, HY | 1 |
| Cho, JH | 1 |
| Shin, ES | 1 |
| Yoon, JH | 1 |
| Yang, TH | 1 |
| Jeong, MH | 1 |
| Lee, JH | 1 |
| Park, JI | 1 |
| Suciu, L | 1 |
| Cristescu, C | 1 |
| Topîrceanu, A | 1 |
| Udrescu, L | 1 |
| Udrescu, M | 1 |
| Buda, V | 1 |
| Tomescu, MC | 1 |
| Kjeldsen, SE | 1 |
| Dzongowski, P | 1 |
| Li, N | 1 |
| Wang, L | 1 |
| Radlmaier, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-center, Randomized, Double-blind, Phase II Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy vs. Monotherapy of Candesartan and Amlodipine for Dose-Finding in Patients With Essential Hypertension[NCT02944734] | Phase 2 | 392 participants (Actual) | Interventional | 2014-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for candesartan cilexetil and Hypertension, Essential
| Article | Year |
|---|---|
Efficacy and Tolerability of Combination Therapy Versus Monotherapy with Candesartan and/or Amlodipine for Dose Finding in Essential Hypertension: A Phase II Multicenter, Randomized, Double-blind Clinical Trial.
Topics: Adult; Aged; Amlodipine; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure | 2017 |
Fixed-dose combination of nifedipine gastrointestinal therapeutic system and candesartan cilexetil in patients with moderate-to-severe essential hypertension: an open-label, long-term safety and efficacy study.
Topics: Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Drug Therapy, Com | 2016 |
1 other study available for candesartan cilexetil and Hypertension, Essential
| Article | Year |
|---|---|
Evaluation of patients diagnosed with essential arterial hypertension through network analysis.
Topics: Adult; Aged; Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Essential | 2016 |